We first demonstrated that the LCK metagene score correlated highly with various other immune-related scores, along with the tumor clinical stage, the prognosis and the mutation status of multiple tumor suppressor genes (BRCA2, TP53 and PTEN) in patients with the four subtypes of breast cancer (luminal A, luminal B, Her-2-like and TNBC). Here, TP53 is linked to breast cancer.